Ep 53: Guest Toni Ribas
Melanoma Matters10 Des 2024

Ep 53: Guest Toni Ribas

Summary

In this episode of Melanoma Matters, hosts James Larkin and Sapna Patel welcome their first live guest, Toni Ribas. The conversation covers the evolution of melanoma treatments, the challenge of treatment resistance, and the importance of clinical trials. The episode emphasizes the need for continuous innovation and the importance of understanding the complexities of the immune system in cancer therapy.


Takeaways

  • Toni shares his journey in oncology, highlighting the importance of scientific exploration.
  • Resistance to therapies remains a major challenge in melanoma treatment.
  • Clinical trials are essential for understanding treatment efficacy and developing new strategies.
  • Chasing complete responses in treatment is crucial for long-term patient outcomes.
  • Patients should not be seen as failing treatments; rather, the focus should be on improving treatment strategies.
  • Understanding the differences between mouse and human immune systems is vital for effective treatment development.


Keywords

melanoma, oncology, immunotherapy, targeted therapy, clinical trials, resistance, checkpoint inhibitors, cancer treatment, patient care, medical research


Sound Bites

"We need to do clinical experimentation."

"We've democratized treatment of melanoma."


Chapters

00:00 Introduction of Guest Toni Ribas

03:29 Toni Ribas' Journey in Oncology

05:44 A Brief History of Melanoma Treatment Before it was Cool

08:26 Understanding Resistance in Melanoma Therapy

11:25 The Role of Targeted Therapy and Immunotherapy

14:35 Clinical Trials and Lessons Learned

17:47 Chasing Complete Responses in Melanoma

20:18 The Future of Melanoma Treatment

22:49 Conclusion and Reflections

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(93)

Ep 88: Negative Adjuvant Doublet Studies (CM915, KV010, RELA098)

Ep 88: Negative Adjuvant Doublet Studies (CM915, KV010, RELA098)

Melanoma Matters: Why Adjuvant Doublet Immunotherapy Fell ShortHobbies - James wishes he was surfing more This episode breaks down three negative adjuvant melanoma trials testing combination immunothe...

1 Sep 22min

Ep 86: Teaser Tudriqev (RP1) FDA Approval

Ep 86: Teaser Tudriqev (RP1) FDA Approval

James asks the big question

25 Aug 10s

Ep 87: INTerpath-001 Press Release - August 2026

Ep 87: INTerpath-001 Press Release - August 2026

In this episode, Sapna and James discuss the INTerpath-001 press release describing primary endpoint (RFS) and key secondary endpoint (DMFS) findings from the randomized phase 3 study of individualize...

25 Aug 12min

Ep 86: Tudriqev (RP1) FDA Approval

Ep 86: Tudriqev (RP1) FDA Approval

In this episode, James and Sapna debate how to pronounce the newest FDA approved treatment for melanoma: T-U-D-R-I-Q-E-VThey discuss the FDA Cell and Gene Therapy Advisory Committee's review of the si...

25 Aug 52min

Ep 85: Surgical considerations for TIL

Ep 85: Surgical considerations for TIL

In this episode, Sapna and James talk tv shows - The Gambler and His Cowboys, Brassic... They discuss the paper from NKI on surgical considerations for TIL harvest published in BJS in 2025. Topics of ...

28 Jul 29min

Ep 84: Merlin CP-GEP and Castle i31-SLNB tests

Ep 84: Merlin CP-GEP and Castle i31-SLNB tests

In this episode, the chin dimple is front and center. James explains the wizarding home of Tintagel in Cornwall to Sapna, situated on a lovely promontory. This episode explores the latest evidence on ...

24 Jul 35min

Ep 83: Guest Megan Othus and Time of Day Administration

Ep 83: Guest Megan Othus and Time of Day Administration

James and Sapna welcome Megan Othus, Professor of Biostatistics at the Fred Hutch Cancer Center and one of the key statisticians at SWOG.Megan talks about growing up in the PNW and going East to get b...

24 Jun 40min

Ep 82: Best of ASCO: 2026

Ep 82: Best of ASCO: 2026

In this episode, James & Sapna tease the size of ASCO and ESMO and number of simultaneous publications.They review the most impactful melanoma and Merkel cell carcinoma presentations from ASCO 2026, f...

13 Jun 1h 4min

Populært innen Helse

fastlegen
rss-gukild-johaug
psykodrama
hvordan-har-du-det-mann
leger-om-livet
relasjonspodden-med-dora-thorhallsdottir-kjersti-idem
lydartikler-fra-aftenposten
rss-skravla-gar
foreldreradet
bak-fasaden-en-reise-i-livet-med-sykepleier-ine
morten-ramm-lar-kakla-ga-til-du-sovner
hjernesterk
hormonelle-frida
klimaks
rss-lopedrommen
g-punktet
rss-kunsten-a-leve
rss-loping-for-nybegynnere
kjed-deg-i-sovn-verdens-kjedeligste-podcast
hverdagspsyken